Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs

NEW YORK (GenomeWeb) – Foundation Medicine said today that it is entering a strategic collaboration with Novartis focused on developing companion diagnostic tests for the company's portfolio of targeted oncology and immuno-oncology drugs.

According to Foundation, the collaboration structure includes development, regulatory support and commercialization of CDx tests using its US Food and Drug Administration-approved comprehensive genomic profiling assay, FoundationOne CDx.

Foundation said that the agreement also allows for global expansion in ex-US markets including Japan, where it has already submitted the larger FoundationOne CDx assay for regulatory approval from the Ministry of Health, Labour and Welfare in partnership with Chugai Pharmaceutical.

Melanie Nallicheri, chief business officer and head of biopharma at Foundation, said in a statement that the collaboration "reaffirms [the company's] commitment to expedite biomarker-driven development and ultimately bring more personalized treatment options to patients."

Additional terms of the deal were not disclosed and Foundation did not specify any drugs or drug candidates that it will be focusing on with Novartis.

In recent months, Foundation has also announced CDx deals with Incyte and Merck for specific therapies in those companies' pipelines.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more